Circulating microRNAs as stable blood-based markers for cancer detection

By P. S. Mitchell, R. K. Parkin, E. Kroh, B. Fritz, S. Wyman, E. Pogosova-Agadjanyan, Amelia C. Peterson, J. Noteboom, K. O'Briant, A. Allen and 10 more. Proceedings of the National Academy of Sciences of the United States of America, 2008

7,971 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e91b525f219422be3abb5d8198e2cbdbf1306dfa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells (2011, background): “These peripheral blood-isolated miRNAs could potentially be used as biomarkers for certain diseases [33,34].”
Molecular genetics of prostate cancer: new prospects for old challenges. (2010, background): “…of CCND1, WNT3A, and BCL2 in prostate cancer have provided an example of potential therapeutic benefit in restoring expression of miRNAs (Bonci et al. 2008), while detection of miRNAs in human plasma has been proposed as a platform for blood-based detection of human cancer (Mitchell et al. 2008).”
Detection of ultra-rare mutations by next-generation sequencing (2012, background): “Clinical applications are rapidly being developed, such as prenatal screening for fetal aneuploidy (6), early detection of cancer (7), and monitoring its response to therapy (8) with nucleic acid-based serum biomarkers.”
Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes (2019, background): “Circulating miR-141 and miR-375 have been shown to be valuable biomarkers for prostate cancer diagnosis [212,213].”
Comparing the MicroRNA Spectrum between Serum and Plasma (2012, background): “Examples of this include the associations of miR-141 with prostate cancer, miR-499 with myocardial infarction, and miR-122 with drug-induced liver injury [3–7].”
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation (2018, background): “Contrary to cellular RNA species, extracellular miRNAs are highly stable, resisting degradation at room temperature for up to 4 days and in deleterious conditions such as boiling, multiple freeze-thaw cycles, and high or low pH (117, 124).”
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. (2016, background): “Thus miRNAs are very stable and their levels can be easily measured in body fluids like blood, serum, cerebrospinal fluid, or urine (173, 174, 194).”
Quantitative and stoichiometric analysis of the microRNA content of exosomes (2014, methodology): “Individual miRNAs were detected by realtime PCR as previously described (30, 36).”
Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced and inflammatory liver diseases (2012, background): “Moreover, various disease-specific circulating miRNA signatures have been reported in recent years.(4,5) MiR-122 is abundant in hepatocytes and recent studies have demonstrated that increased circulating miR-122 is associated with hepatitis C virus (HCV) infection, hepatocellular carcinoma (HCC), ac”
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis (2020, methodology): “utilized them for the examination of diffuse large B-cell lymphoma in the serum of patients [84,85], and ever since, their potential use as biomarkers has been mentioned in literature for numerous diseases.”